Physician profile
Marcellus Cephas
NPI 1134116007
$10,354.70
in general payments reported to CMS, 2019-2025
24 companies · $736 in 2025
The $736 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $3,701 · 2021: $4,040 · 2022: $235 · 2023: $566 · 2024: $418 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.38 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,719.34 | 2021-2025 | Vraylar |
| Allergan, INC. | $3,530.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $559.46 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $473.89 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $412.75 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $251.74 | 2019-2023 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.61 | 2021-2025 | Caplyta |
| Alkermes, INC. | $171.04 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $146.39 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $120.23 | 2019-2025 | |
| Indivior INC. | $108.82 | 2020-2025 | Sublocade, Perseris |
| Ironshore Pharmaceuticals INC. | $102.79 | 2021-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $93.46 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $75.64 | 2020-2021 | |
| Corium, LLC | $61.97 | 2023-2024 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.56 | 2024 | Cobenfy |
| Braeburn INC. | $35.63 | 2023 | Brixadi |
| Almatica Pharma LLC | $34.68 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2020 | |
| Shire North American Group INC | $30.37 | 2019 | |
| Bausch Health US, LLC | $22.63 | 2022 | |
| Tris Pharma INC | $21.10 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcellus Cephas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.